Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts

Abstract

Several registries and quality improvement initiatives have focused on assessing and improving secondary prevention of CVD in India. While the Treatment and Outcomes of Acute Coronary Syndromes in India (CREATE), Indian Heart Rhythm Society-Atrial Fibrillation (IHRS-AF), and Trivandrum Heart Failure (THF) registries are limited to collecting data, the Tamil Nadu–ST-Segment Elevation Myocardial Infarction (TN-STEMI) program was aimed at examining and improving access to revascularization after an ST-elevation myocardial infarction (STEMI). The Acute Coronary Syndromes: Quality Improvement in Kerala (ACS-QUIK) study recruited hospitals from the Kerala ACS registry to assess a quality improvement kit for patients with ACS while the Practice Innovation and Clinical Excellence India Quality Improvement Program (PIQIP) provides valuable data on outpatient CVD quality of care. Collaborative efforts between health professionals are needed to assess further gaps in knowledge and policy makers to utilize new and existing data to drive policy-making.

Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS

“…As the clinical presentation of cardiovascular diseases is seen at a younger age in India and there is a suboptimal rate of guideline recommended management practices, more primary and secondary prevention strategies are required for the management of the disease. The existing gap between the clinical guidelines and the current practice need to be addressed by the collaborative efforts from the public private hospitals, newer interventions from the ministry of health and family welfare, and from the adequate support from the academic institutions [ 24 , 25 ].…”

A Delphi Study to Prioritize Evidence-Based Strategies for Cardiovascular Disease Care in India

“…In the Indian context, barriers to CVD care are further exacerbated by the economic burden on patients and their family from treatment (Mohanan et al, 2019 ), poor understanding of the need for lifelong medication particularly for diseases like CVD that are frequently free of symptoms, and poor access and supply of evidence-based treatments to a vast majority of the population in need of these treatments. Bridging these implementation gaps require multidisciplinary collaborations between policymakers, academia, implementation partners, trained health workforce, and public–private partnerships (Collaborators et al, 2021 ; Rehman et al, 2020 ). Further, contextual adaptation and implementation of successful/standardized CVD care models are important due to significant variations in CVD care quality across states and socio-demographic groups within India (Geldsetzer et al, 2018 ).…”